Chronic Anergic-anhedonic Depression Open Trial
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Proportion of patients in remission; Remission time; Survival curves for remissions and responses
研究概览
简要总结
A form of depression called 'dopamine-sensitive anergic-anhedonic syndrome is usually resistant to standard therapies (TRAD). On the other hand, they respond to dopaminergic approaches for which recommendations have been developed: DATA ('Dopaminergic Antidepressant Therapy Algorithm'). These are two stages starting with non-selective monoamineoxidase inhibitors (MAOI) or dopamine D2 receptor agonists (D2RAG) in 'monotherapy' (DATA1) and proposing to combine them in the event of a partial response (DATA2).
The effectiveness of this approach in the management of TRAD has not yet been evaluated in routine care.
The aim of this study is to evaluate the feasibility and effectiveness in routine care of the DATA recommendations in the management of TRAD presenting to a specialized consultation for resistant depression (short and long-term results).
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Major patient (≥18 years old)
- •Man or woman
- •Patient covered for consultation at the Expert Resistant Depression Center of Alsace (CEDRA) (CHU-Strasbourg branch) for TRAD between 01 January 2013 and 31 March 2023
- •Patient not opposing to the reuse of their data for the purposes of this research
排除标准
- •Patient having expressed opposition to participating in the study
- •Patient under judicial protection
- •Patient under guardianship or curatorship
结局指标
主要结局
Proportion of patients in remission; Remission time; Survival curves for remissions and responses
时间窗: 3 months after the patient was taken care of at the Strasbourg University Hospital
次要结局
未报告次要终点